Relation Therapeutics announces launch of flagship integrated wet–dry laboratory at the heart of London’s Knowledge Quarter
22.2.2023 09:00:00 EET | Business Wire | Press release
Relation Therapeutics, a leader in the use of high-resolution biology, machine learning and clinical insights to discover life-changing medicines, announced today the opening of their flagship integrated wet–dry laboratory. The laboratory and offices comprise 5,500 sq ft, located at the heart of London’s Knowledge Quarter, in close reach of collaborators and partners including globally renowned academic research centres and major pharma companies. Over the last year the company has grown to a 35-strong cross-disciplinary seed-stage company. The new space is another step forward in realising Relation’s ambition to establish a novel transformational approach to drug discovery.
The integrated wet–dry laboratory’s unique value for drug discovery comes from efficiently combining the most sophisticated functional genomic techniques with extraordinary computational power and machine learning. With the acquisition of genomic data from human cells, Relation obtains direct insights into critical biological relationships, which are then fed directly into the dry laboratory’s machine learning engine. The engine then automatically requests new experiments to improve its predictive ability, cutting through an otherwise undecipherable combinatorial space. This sequence of experiments is the essence of Relation’s Lab-in-the-Loop and by uniting these two technologies Relation aims to radically improve the probability of success of drug discovery and development.
“Deploying machine learning to understand such a vast array of interactions between genes, proteins and drugs holds extraordinary potential for discovering new drugs,” said Sir Paul Nurse, CEO of the Francis Crick Institute who alongside the executive team led the official opening. “It is pleasing to see Relation Therapeutics joining the Crick and other innovative bioscience enterprises in the Knowledge Quarter, further enhancing London’s already internationally distinguished bio ecosystem.”
Relation Therapeutics further announced the appointment of Dr. Edith M. Hessel, a former GSK R&D executive, as Chief Scientific Officer (CSO). Dr. Hessel will lead the drug discovery direction of the company and the progression of its pipeline to the clinic. Dr. Hessel has successfully pioneered the development of novel target discovery platforms, advanced therapeutics from inception to clinical proof of concept, and has extensive experience in founding biotech companies. As a VP at GSK, Dr. Hessel built the Refractory Respiratory Inflammation Discovery Performance Unit, which added multiple novel targets to GSK’s pipeline.
“I am absolutely delighted to be part of Relation’s mission to transform drug discovery, probing unexplored molecular target spaces for potentially life-changing medicines,” said Edith Hessel. “Relation combines a world-class team with cutting-edge technology, including access to NVIDIA’s Cambridge-1, the UK’s most powerful super-computer. Utilising first-class computational capacity to explore experimental data, clinical insights and high-resolution biology will transform drug discovery as we know it, allowing us to develop better medicines for patients.”
In addition, Relation shared their vision for indication selection, which uses a proprietary machine learning engine - SelectomaticTM - to recommend those indications where Relation’s integrated platform enables the development of transformational therapeutics. Application of this engine led to the initiation of osteoporosis as the first disease that Relation will pursue. Osteoporosis, a metabolic bone disease, is characterised by low bone density and deterioration of bone architecture, increasing the risk of fractures.1 It is estimated that there are approximately ten million people with osteoporosis in the USA alone,1 with nearly one million considered to be patients at high risk of fractures. Furthermore, in Europe, 32 million people over 50 are estimated to have osteoporosis.2 Current treatment options have a number of limitations, including safety concerns, low uptake, and limited duration of efficacy.
“The use of single-cell profiling allows our scientists to understand bone biology with exquisite detail and provides us with the unique opportunity to be at the forefront of finding a next-generation therapy for osteoporosis,” said Dr. David Roblin, Chief Executive Officer. “This access to rich single-cell data perfectly enables the power of our machine learning engine in a disease of significant unmet need.”
In their mission to discover life-changing medicines, the team at Relation Therapeutics leverages their extensive experience in building successful biotechnology businesses. This includes Dr. Charlie Roberts, the Chairperson of Relation, who is the co-founder of Freenome, a San Francisco-based company that has raised over $1bn from investors including Roche and Novartis. In June 2022, DCVC and Magnetic Ventures co-led a $25-million round of seed financing, with participation from Khosla Ventures, OMERS Ventures, and Firstminute Capital, among others.
To learn more about Relation Therapeutics, please visit: https://www.relationrx.com/.
About Relation
Relation is a biotechnology company focused on leveraging computational and experimental techniques to understand biology better. Central to Relation’s approach is its integrated wet–dry laboratory which leverages human genetics, single-cell profiling and machine learning to generate new insights with real translational validity. The company is located in London.
References
- Wright N, Looker A, Saag K, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res. 2014;29(11):2520–2526.
- Kanis JA, et al., SCOPE 2021: a New Scorecard for Osteoporosis in Europe, Arch Osteoporos, 2021, 16(1):82.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230221005853/en/
Contact information
For further queries, please contact:
Dr. Rosie Rodriguez – SVP, Growth, Relation Therapeutics: rosie@relationrx.com; +44 7511 183023
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Povofortay ® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa16.11.2026 23:30:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Povofortay® (povorcitinib) 45 mg and 75 mg for the treatment of eligible adults with moderate to severe hidradenitis suppurativa (HS). “The European Commission approval of Povofortay marks an important milestone for Incyte, advancing a key growth driver for our business and bringing a new treatment option to people living with HS, a chronic and often debilitating disease,” 2,3 said Bill Meury, Chief Executive Officer, Incyte."As the first and only once-daily oral treatment approved in the European Union for eligible adults with moderate to severe HS, Povofortay gives physicians an important new option for their patients.” The approval is based on results from the pivotal STOP-HS1 (NCT05620823) and STOP-HS2 (NCT05620836) trials evaluating the safety and efficacy of Povofortay in patients with moderate to severe HS.2 Data from the Phase 3 STOP-HS program demonstrated Povofortay’s clinically meaningful and
Moody’s Names Timothy Bhatt as Chief Information Officer16.11.2026 23:00:00 EET | Press release
Moody’s Corporation (NYSE: MCO) announced today that it has named Tim Bhatt to the newly created role of Chief Information Officer (CIO), effective December 7th, and that he will join the company’s Executive Leadership Team. Mr. Bhatt, who has served as Chief Technology Officer (CTO) of Moody’s Ratings since 2018, will also continue in that role. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116893391/en/ Timothy Bhatt, Chief Information Officer, Moody's As CIO, Mr. Bhatt will lead Moody’s enterprise technology strategy, AI enablement, and information security, with responsibility for the company’s technology services and operations and cybersecurity teams. He will further modernize how Moody’s operates, bringing together human expertise, trusted data and AI agents to reimagine enterprise workflows and move AI agents from pilots into everyday work. Mr. Bhatt will also continue as Chief Technology Officer of Moody’s Ratin
Lattice Extends Space Heritage with On-Orbit Milestone in TESAT Optical Communication Terminals16.11.2026 23:00:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced that its low power, radiation-resilient Lattice Nexus™ FPGAs have surpassed one year of on-orbit operation in TESAT optical communication terminals. Since launch, the FPGAs have delivered consistent performance in the demanding application of space-based laser communication at 10 Gbps, adding to Lattice’s space heritage of thousands of FPGAs launched to date. TESAT has flown optical communication terminals on GEO and LEO missions for more than a decade, supplying broadband constellations and institutional programs. For the redesign of its terminal electronics, Lattice Nexus FPGAs addressed TESAT’s requirements for radiation tolerance, low power, and board footprint. Built on 28 nm fully depleted silicon-on-insulator (FD-SOI) process technology, the Nexus platform is well suited to a terminal that must run for years without maintenance. “As optical links and onboard processing
New Holiday Data From Xsolla Shows Players Are Shopping, Gifting, and Choosing Brands Inside Video Games16.11.2026 19:00:00 EET | Press release
Xsolla (USA), Inc., a global commerce company, today announced a new data and insights report on how players shop, spend, and respond to brands during the holiday season. Titled “Why Video Games Belong in Your Holiday Commerce Strategy,” the report draws on direct answers from more than 4,000 players, gathered through opt-in rewarded surveys on Xsolla Offerwall. Players chose to take part and received a reward for sharing, which makes the data first-party and consent-based. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111104582/en/ Graphic: Xsolla The research builds on the conversation Xsolla opened at Advertising Week New York 2026 about how brands can reach players in more ways through video games. Combined with Xsolla’s insights into in-game purchasing behavior across an audience of over 300 million players, the survey shows an engaged audience with established spending habits: 84% of respondents call themselves gam
IQM Supports NVIDIA’s Work to Make Quantum Computers Schedulable in Slurm16.11.2026 18:00:00 EET | Press release
IQM Quantum Computers (Nasdaq: IQMX), a global leader in superconducting quantum computers, today announced at SC26 in Chicago its support for NVIDIA’s investment in making quantum processing units (QPUs) a schedulable resource in the Slurm workload manager by integrating IQM quantum computers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116814640/en/ NVIDIA is making quantum computers a schedulable resource in Slurm by integrating IQM quantum computers. NVIDIA, which has committed to keeping Slurm open source and vendor neutral, announced that Slurm 26.11 adds plugin support for Hierarchical Resources (HRES), allowing a supercomputing center to describe a QPU as a shared, cluster-level resource and connect it to external services, such as the software that manages the device. Until now, quantum computers have not fit the scheduling models Slurm uses for CPUs and GPUs, so integrations have often been built separately f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
